MOR vs. CTLT, ROIV, ELAN, ASND, LEGN, CERE, VKTX, ITCI, JAZZ, and BPMC
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.
Catalent received 615 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 59.15% of users gave Catalent an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
Catalent has a net margin of -26.61% compared to Catalent's net margin of -226.79%. MorphoSys' return on equity of -2.73% beat Catalent's return on equity.
MorphoSys has lower revenue, but higher earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
18.4% of MorphoSys shares are owned by institutional investors. 0.3% of Catalent shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Catalent had 6 more articles in the media than MorphoSys. MarketBeat recorded 10 mentions for Catalent and 4 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.74 beat Catalent's score of -0.07 indicating that Catalent is being referred to more favorably in the media.
Catalent presently has a consensus target price of $53.14, indicating a potential downside of 1.22%. MorphoSys has a consensus target price of $11.78, indicating a potential downside of 35.94%. Given MorphoSys' higher possible upside, equities research analysts plainly believe Catalent is more favorable than MorphoSys.
Catalent has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Summary
Catalent beats MorphoSys on 12 of the 18 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
